Literature DB >> 11590582

Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 cases.

H Amital1, Y Levy, C Davidson, I Lundberg, A Harju, Y Kosach, R A Asherson, Y Shoenfeld.   

Abstract

OBJECTIVE: The antiphospholipid syndrome is characterized by venous and arterial thrombotic events that are often recurrent, thrombocytopenia, recurrent fetal loss, and elevated titers of antiphospholipid antibodies. A subtype of patients with a particularly overwhelming clinical picture has been termed catastrophic antiphospholipid syndrome (CAPS). In this report, we present 2 patients who exhibited a similar multisystem disorder associated with gangrenous changes in the lower extremities.
METHODS: Two patients with CAPS are presented, highlighting the impact of this disorder on the patients and the response to various therapeutic modalities.
RESULTS: Both patients had pulmonary, cardiac, cutaneous, and neurologic findings consistent with CAPS. In addition, they had large purulent leg ulcers associated with livedo reticularis. Amputation of the legs in each case induced remission of the systemic illness.
CONCLUSIONS: We believe that infection plays a significant role in the pathogenesis and amplification of the antiphospholipid syndrome. In certain patients, this association probably is mediated via immune mechanisms, which also enhance the genesis of atherosclerosis. After the foci of infection (suppurative leg ulcers) were removed, the underlying illness improved. These case studies provide an opportunity to study the interrelationship between several confounding factors that converge and lead to the development of this autoimmune condition. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Year:  2001        PMID: 11590582     DOI: 10.1053/sarh.2001.27660

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  8 in total

Review 1.  Catastrophic antiphospholipid syndrome.

Authors:  Ronald A Asherson; Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

Review 2.  Antiphospholipid antibodies and infections.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

Review 3.  Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.

Authors:  R Cervera; R A Asherson; M L Acevedo; J A Gómez-Puerta; G Espinosa; G De La Red; V Gil; M Ramos-Casals; M García-Carrasco; M Ingelmo; J Font
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

Review 4.  Infectious origin of the antiphospholipid syndrome.

Authors:  Y Shoenfeld; M Blank; R Cervera; J Font; E Raschi; P-L Meroni
Journal:  Ann Rheum Dis       Date:  2006-01       Impact factor: 19.103

5.  Catastrophic antiphospholipid syndrome triggered by sepsis.

Authors:  Susan Kim; Neal K Moskowitz; Edward F DiCarlo; Anne R Bass; Doruk Erkan; Michael D Lockshin
Journal:  HSS J       Date:  2008-12-19

Review 6.  Malignancies and catastrophic anti-phospholipid syndrome.

Authors:  Wolfgang Miesbach
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

7.  The role of malignancies in patients with catastrophic anti-phospholipid (Asherson's) syndrome.

Authors:  W Miesbach; R A Asherson; R Cervera; Y Shoenfeld; J Gomez Puerta; G Espinosa; S Bucciarelli
Journal:  Clin Rheumatol       Date:  2007-05-24       Impact factor: 2.980

Review 8.  Antiphospholipid syndrome infectious origin.

Authors:  M Blank; R A Asherson; R Cervera; Y Shoenfeld
Journal:  J Clin Immunol       Date:  2004-01       Impact factor: 8.542

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.